Related Experiment Video
Updated: May 2, 2026

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
Transvenous Extrahepatic Portosystemic Shunts (TEPS): Intravascular Ultrasound-Guided Creation of Portocaval,
Aakash N Gupta1, John D Louie2, Daniel Y Sze2
1Division of Interventional Radiology, Stanford University, Stanford, California. Electronic address: https://twitter.com/aakashng17.
Purpose:
To evaluate the feasibility and long-term safety and effectiveness of intravascular ultrasound (IVUS)-guided transvenous extrahepatic portosystemic shunt (TEPS) creation for patients unsuitable for transjugular intrahepatic portosystemic shunt (TIPS) creation.
Materials And Methods:
A single-center, retrospective study was performed in 23 patients (19 adult and 4 pediatric; median, 55.7 years; range, 8-75 years; 13 [57%] male) who underwent 24 TEPS creations for variceal bleeding (n = 20, 83%), refractory ascites (n = 3, 13%), or preoperative portal decompression (n = 1, 4%). Rationale for extrahepatic shunt included chronic portal vein occlusion (n = 17, 71%), chronic superior mesenteric vein occlusion (n = 2, 8%), obstructed intrahepatic path (n = 3, 13%), complex Budd-Chiari syndrome (n = 1, 4%), and intentional portosplenic blood flow separation (n = 1, 4%). Baseline characteristics included active cancer (n = 6, 27%), cirrhosis (n = 9, 41%), and liver transplant (n = 4, 22%). Primary outcomes were technical success and periprocedural adverse events. Secondary outcomes were patency, delayed adverse events, and overall survival (OS).
Results:
Technical success was 100% for portocaval (n = 16, 67%), superior mesocaval (n = 5, 21%), inferior mesocaval (n = 1, 4%), and splenorenal (n = 2, 8%) shunts. Periprocedural adverse events included 9 Grade 1-2 events (38%) and 1 Grade 3 acute kidney injury (4%). One-year primary patency was 100%, and 3-year primary assisted patency was 100%. Recurrent variceal bleeding developed in 4 patients (17%); refractory ascites did not recur. Eight patients (36%) developed hepatic encephalopathy, managed medically. Hepatopulmonary and portopulmonary syndromes occurred in 1 patient each (4%; 4%). Median OS was 38.4 months, shorter in patients with active cancer (10.4 vs 104.8 months, P = .026).
Conclusions:
IVUS-guided TEPS creation is feasible, effective, and durable in patients with complications of portal hypertension not suitable for conventional recanalization or TIPS creation.
Related Concept Videos
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Portal Hypertension
Hepatic Encephalopathy

